Denmark· DK-28103159100
Xylometazolin "Orifarm" menthol ukonserveret
A xylometazoline product containing xylometazolin, registered in Denmark by Orifarm Healthcare A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Xylometazoline is registered in 14 of 19 countries.
Countries holding a registration under ATC R01AA07 (xylometazoline), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Xylometazoline · ATC R01AA07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Xylometazolin
- Manufacturer
- Orifarm Healthcare A/S
- Country
- Denmark (DK)
- ATC code
- R01AA07
- ATC class
- Xylometazoline
- Defined daily dose
- 0.8 mg, N
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28103159100
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for xylometazoline.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Xylometazoline · interactions on record
63 records
- 6 severe
- 54 moderate
Most severe, free to view
- MethylergometrineG02AB01severe
- DihydroergotamineN02CA01severe
- ErgotamineN02CA02severe
- MethysergideN02CA04severe
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R01AA07
Xylometazoline, as other registers publish it.
- NetherlandsAlbert Heijn Kinderneusspray Xylometazoline HCl 0,5 mg/ml, neusspray, oplossingHealthypharm B.V.
- NetherlandsAlbert Heijn Neusdruppels Xylometazoline HCl 1 mg/ml, neusdruppels, oplossingHealthypharm B.V.
- NetherlandsAlbert Heijn Neusspray Xylometazoline HCl 1 mg/ml, neusspray, oplossingHealthypharm B.V.
- NetherlandsAlbert Heijn Xylometazoline HCl Menthol 1 mg/ml, neusspray, oplossingOTC Medical B.V.
- NetherlandsAlbert Heijn Xylometazoline HCl Menthol 1 mg/ml, neusspray, oplossingHealthypharm B.V.
- FinlandBafunasalMcNeil, a division of Janssen- Cilag Oy
- NetherlandsColdrex Xylosel Neusspray 0,5 mg/ml, oplossingOmega Pharma Nederland B.V.
- NetherlandsColdrex Xylosel Neusspray 1 mg/ml, oplossingOmega Pharma Nederland B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7d3e5bf-1ce2-4316-af52-3f84fc913e4f GET /v1/drugs/b7d3e5bf-1ce2-4316-af52-3f84fc913e4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "næsespray, opløsning",
"source": "dkma",
"strength": "1 mg/ml",
"auth_role": "RMS",
"dk_drugid": "28103159100",
"substance": "Xylometazolin",
"auth_procedure": "MRP",
"in_medicinpriser": false,
"registration_date_serial": "37582"
}See everything about xylometazoline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.